deleted in malignant brain tumors 1Genealiases: GP340 · SAG · SALSA · muclin
Q-omics provides the consensus-scored DMBT1 profile across patient tissues and cancer cell-line models. DMBT1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, DMBT1 is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, DMBT1 RNA expression shows 13,782 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, LUAD, and LSCC as cancer lineages where DMBT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DMBT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DMBT1 survival associations across molecular data types. DMBT1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (10) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DMBT1 RNA expression–survival associations across cancer types. High DMBT1 expression shows unfavorable associations in KIRP, UVM, STAD and KICH, but favorable associations in MESO and THCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for DMBT1 RNA expression.
This table summarizes DMBT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in LUAD for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for DMBT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DMBT1 shows lower tumor expression in LUAD, BRCA, HNSC and LUSC and higher tumor expression in KIRC and THCA. The LUAD box plot shows higher DMBT1 RNA expression in normal versus tumor tissue (log2 FC = −3.039, t-test p < 0.001).
This table shows molecular features associated with DMBT1 in patient tissues and cancer cell lines. In patient samples, DMBT1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, DMBT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LARGE_INTESTINE.
